A Phase 2 interventional study of COVID-19 mRNA Vaccine (ZSVG-02-O) and COVID-19 mRNA Vaccine (ZSVG-02-O) in SARS-CoV-2 Infection, sponsored by CNBG-Virogin Biotech (Shanghai) Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-08.
Sponsored by CNBG-Virogin Biotech (Shanghai) Ltd. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.
Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 2, and was the 9th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:
ANRS, Emerging Infectious Diseases · Sites in France
Ages 18–84 · Healthy volunteers
CNBG-Virogin Biotech (Shanghai) Ltd. · Sites in China
Ages 18–99 · Healthy volunteers
By country, each count listing its studies:
mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2021; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 980 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 157 across the 12 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
CNBG-Virogin Biotech (Shanghai) Ltd. is the lead sponsor of 8 studies on the registry; 7 are open to participants now.
CNBG-Virogin Biotech (Shanghai) Ltd. has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the immunogenicity and safety of a COVID-19 mRNA vaccine (ZSVG-02-O) in a healthy population aged 18 years and older.
This study uses a randomized, blinded and controlled design, with age stratification of 18-59 years and ≥60 years , including the test vaccine at different doses (30 μg and 60 μg) and an active control vaccine.
A total of 980 subjects will be enrolled in this study. 490 subjects aged 18-59 years will be randomly assigned to cohort A1 (test vaccine dose 1), A2 (test vaccine dose 2) and A3 (control vaccine) for the 2-dose regimen (0,28-day) and to cohort A4 (test vaccine dose 1), A5 (test vaccine dose 2) and A6 (active control) for the 1-dose regimen in a ratio of 3:3:1:3:3:1. Another 490 subjects aged 60 years or older will be randomized to cohort B1 (test vaccine dose 1), B2 (test vaccine dose 2) and B3 (active control) for the 2-dose regimen (0,28-day), and cohort B4 (test vaccine dose 1), B5 (test vaccine dose 2) and B6 (control vaccine) for the 1-dose regimen in a ratio of 3:3:1:3:3:1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)
Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)
Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated
Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)
Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)
Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated
30 μg
60 μg
COVILO
Geometric mean titre (GMT) and 4-fold increasing rate of neutralizing antibodies (NAbs) against SARS-CoV-2 on 28 days after full vaccination
Geometric mean titre (GMT) and 4-fold increasing rate of neutralizing antibodies (NAbs) against SARS-CoV-2 on 28 days after full vaccination
Time frame: 28 days after full immunisation
GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 14 days after full vaccination
GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 14 days after full vaccination
Time frame: 14 days after full immunisation
GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 7 days after the first immunisation
GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 7 days after the first immunisation
Time frame: 7 days after the first immunisation
Proportion of NAbs against SARS-CoV-2 titres≥1:16, ≥1:32 and ≥1:64 on 14 and 28 days after full immunisation
Proportion of NAbs against SARS-CoV-2 titres≥1:16, ≥1:32 and ≥1:64 on 14 and 28 days after full immunisation
Time frame: 14 days and 28 days after full immunisation
GMT, 4-fold increasing rate and ratio of antibody titres ≥1:16, ≥1:32 and ≥1:64 for NAbs against SARS-CoV-2 on 90 and 180 days after full immunisation
GMT, 4-fold increasing rate and ratio of antibody titres ≥1:16, ≥1:32 and ≥1:64 for NAbs against SARS-CoV-2 on 90 and 180 days after full immunisation
Time frame: 90 days and 180 days after full immunisation
Incidence and severity of adverse event (AE) within 30 minutes of each dose of vaccination
Incidence and severity of AE within 30 minutes of each dose of vaccination
Time frame: From the start of each immunisation until 30 minutes after each immunisation
Incidence and severity of adverse reactions/events 0-14 days after each dose of vaccination
Incidence and severity of adverse reactions/events 0-14 days after each dose of vaccination
Time frame: Day 0~Day 14 after each immunisation
Incidence and severity of adverse reactions/events 15-28 days after each dose of vaccination
Incidence and severity of adverse reactions/events 15-28 days after each dose of vaccination
Time frame: Day 15~Day 28 after each immunisation
Incidence of serious adverse event (SAE) from the start of vaccination to 12 months after full vaccination
Incidence of SAE from the start of vaccination to 12 months after full vaccination
Time frame: From the first dose of immunisation to 12 months after full immunisation
Changes in cytokine levels in Th1/Th2 cells induced by S protein
Cytokine \[IFN-γ, interleukin(IL)-4, IL-2\] levels in Th1/Th2 cells changed from pre-dose to 28 days after the full immunisation
Time frame: From before the first dose of immunisation to 28 days after full immunisation
Cross-neutralisation against different SARS-CoV-2 variants
The cross-neutralization effect of the mRNA vaccine (Omicron strain) against different SARS-CoV-2 variants (ancestral strain, Omicron strain and main circulating strain)
Time frame: From the first dose of immunisation to 28 days after full immunisation
Ran from Jul 2023 to primary completion in Oct 2023, 3 months.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 3 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA COVID-19 Vaccine
CNBG-Virogin Biotech (Shanghai) Ltd.